FOSTER CITY, CALIF., – December 7, 1998 ..... DepoMed, Inc. (AMEX: DMI) today announced the appointment of Bret Berner, Ph.D., as Vice President, Product Development. Dr. Berner was most recently Vice President, Development at Cygnus Therapeutic Systems.

FOSTER CITY, CALIF., - November 6, 1998 .. DepoMed, Inc. (Nasdaq: DPMD) announced that its common stock and warrants (Nasdaq: DPMDW) have been approved for listing on the American Stock Exchange under the symbols "DMI" and "DMIW," respectively. The Company expects trading to begin on Monday,

FOSTER CITY, CALIF., - November 2, 1998 ..... DepoMed, Inc. (Nasdaq: DPMD) announced today revenues of $217,687 for the quarter ended September 30, 1998 compared to $104,454 for the quarter ended September 30, 1997. The Company reported a net loss of $645,496, or $0.10 per share, for the quarter

FOSTER CITY, CALIF., - August 5, 1998 ..... DepoMed, Inc. (Nasdaq: DPMD) announced today revenues of $130,000 for the quarter ended June 30, 1998 compared to $225,000 for the quarter ended June 30, 1997. The Company reported a loss of $586,000, or $0.09 per share, for the quarter ended June 30,

FOSTER CITY, CALIF., - May 15, 1998 ..... DepoMed, Inc. (Nasdaq: DPMD) announced today revenues of $110,000 for the quarter ended March 31, 1998 compared to $127,000 for the quarter ended March 31, 1997. The Company reported a loss of $493,000, or $0.08 per share, for the quarter ended March 31,

FOSTER CITY, CA - March 19, 1998 - DepoMed, Inc. (Nasdaq: DPMD) reported revenues of $605,000 for the year ended December 31, 1997, resulting from research and development payments in connection with its ongoing development work with Bristol-Myers Squibb. Revenues were $318,000 in 1996.

FOSTER CITY, CA - March 4, 1998 - DepoMed, Inc. (Nasdaq: DPMD) announced that it has entered into a research collaboration with the R. W. Johnson Pharmaceutical Research Institute (PRI), a Johnson & Johnson unit, to study the feasibility of an orally administered, controlled release pharmaceutical

FOSTER CITY, CA - February 24, 1998 - DepoMed, Inc. (Nasdaq: DPMD) announced that it has completed a private placement of common stock for $8 million, with net proceeds of approximately $7.5 million to the Company. Investors agreed to a lock-up provision until November 6th, 1998, the one-year

FOSTER CITY, CA - February 12, 1998 - DepoMed, Inc. today announced that Dr. W. Leigh Thompson was elected to the Board of Directors on January 30, 1998. Dr. Thompson (59) was previously Chief Scientific Officer at Eli Lilly before founding Profound Quality Resources, Ltd., a private healthcare

FOSTER CITY, CA - December 1, 1997 - DepoMed, Inc. (Nasdaq: DPMDU) today announced that, effective December 1, 1997, the Common Stock and Warrants comprising the Company's Units will become detachable and separately transferable. Also effective as of December 1, 1997, the shares of Common Stock and